28457994|t|Increase in acid sphingomyelinase level in human retinal endothelial cells and CD34(+) circulating angiogenic cells isolated from diabetic individuals is associated with dysfunctional retinal vasculature and vascular repair process in diabetes
28457994|a|Diabetic retinopathy is a microvascular disease that results from retinal vascular degeneration and defective repair due to diabetes - induced endothelial progenitor dysfunction. Understanding key molecular factors involved in vascular degeneration and repair is paramount for developing effective diabetic retinopathy treatment strategies. We propose that diabetes - induced activation of acid sphingomyelinase (ASM) plays essential role in retinal endothelial and CD34(+) circulating angiogenic cell (CAC) dysfunction in diabetes. Human retinal endothelial cells (HRECs) isolated from control and diabetic donor tissue and human CD34(+) CACs from control and diabetic patients were used in this study. ASM messenger RNA and protein expression were assessed by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. To evaluate the effect of diabetes - induced ASM on HRECs and CD34(+) CACs function, tube formation, CAC incorporation into endothelial tubes, and diurnal release of CD34(+) CACs in diabetic individuals were determined. ASM expression level was significantly increased in HRECs isolated from diabetic compared with control donor tissue, as well as CD34(+) CACs and plasma of diabetic patients. A significant decrease in tube area was observed in HRECs from diabetic donors compared with control HRECs. The tube formation deficiency was associated with increased expression of ASM in diabetic HRECs. Moreover, diabetic CD34(+) CACs with high ASM showed defective incorporation into endothelial tubes. Diurnal release of CD34(+) CACs was disrupted with the rhythmicity lost in diabetic patients. Collectively, these findings support that diabetes - induced ASM upregulation has a marked detrimental effect on both retinal endothelial cells and CACs.
28457994	12	33	acid sphingomyelinase	T103	UMLS:C0599122
28457994	43	48	human	T204	UMLS:C0086418
28457994	49	56	retinal	T017	UMLS:C0035298
28457994	57	74	endothelial cells	T017	UMLS:C0225336
28457994	79	115	CD34(+) circulating angiogenic cells	T017	UMLS:C0882849
28457994	130	138	diabetic	T038	UMLS:C0011847
28457994	139	150	individuals	T098	UMLS:C0237401
28457994	170	203	dysfunctional retinal vasculature	T017	UMLS:C4024753
28457994	235	243	diabetes	T038	UMLS:C0011847
28457994	244	264	Diabetic retinopathy	T038	UMLS:C0011884
28457994	310	317	retinal	T017	UMLS:C0035298
28457994	318	339	vascular degeneration	T038	UMLS:C1281300
28457994	354	360	repair	T058	UMLS:C1705181
28457994	368	376	diabetes	T038	UMLS:C0011847
28457994	387	421	endothelial progenitor dysfunction	T038	UMLS:C0856169
28457994	471	492	vascular degeneration	T038	UMLS:C1281300
28457994	497	503	repair	T058	UMLS:C1705181
28457994	542	562	diabetic retinopathy	T038	UMLS:C0011884
28457994	563	572	treatment	T058	UMLS:C0087111
28457994	601	609	diabetes	T038	UMLS:C0011847
28457994	634	655	acid sphingomyelinase	T103	UMLS:C0599122
28457994	657	660	ASM	T103	UMLS:C0599122
28457994	686	693	retinal	T017	UMLS:C0035298
28457994	694	705	endothelial	T017	UMLS:C0225336
28457994	710	745	CD34(+) circulating angiogenic cell	T017	UMLS:C0882849
28457994	747	750	CAC	T017	UMLS:C0882849
28457994	767	775	diabetes	T038	UMLS:C0011847
28457994	777	782	Human	T204	UMLS:C0086418
28457994	783	790	retinal	T017	UMLS:C0035298
28457994	791	808	endothelial cells	T017	UMLS:C0225336
28457994	810	815	HRECs	T017	UMLS:C0225336
28457994	843	851	diabetic	T038	UMLS:C0011847
28457994	852	857	donor	T098	UMLS:C0013018
28457994	858	864	tissue	T017	UMLS:C0040300
28457994	869	874	human	T204	UMLS:C0086418
28457994	875	887	CD34(+) CACs	T017	UMLS:C0882849
28457994	905	913	diabetic	T038	UMLS:C0011847
28457994	948	951	ASM	T017	UMLS:C1420259
28457994	952	965	messenger RNA	T103	UMLS:C0035696
28457994	970	988	protein expression	T038	UMLS:C1171362
28457994	1006	1044	quantitative polymerase chain reaction	T062	UMLS:C3179034
28457994	1049	1082	enzyme-linked immunosorbent assay	T058	UMLS:C0014441
28457994	1124	1132	diabetes	T038	UMLS:C0011847
28457994	1143	1146	ASM	T103	UMLS:C0599122
28457994	1150	1155	HRECs	T017	UMLS:C0225336
28457994	1160	1172	CD34(+) CACs	T017	UMLS:C0882849
28457994	1173	1181	function	T038	UMLS:C0007613
28457994	1183	1197	tube formation	T038	UMLS:C2752214
28457994	1199	1202	CAC	T017	UMLS:C0882849
28457994	1222	1239	endothelial tubes	T017	UMLS:C0014257
28457994	1264	1276	CD34(+) CACs	T017	UMLS:C0882849
28457994	1280	1288	diabetic	T038	UMLS:C0011847
28457994	1289	1300	individuals	T098	UMLS:C0237401
28457994	1318	1321	ASM	T103	UMLS:C0599122
28457994	1370	1375	HRECs	T017	UMLS:C0225336
28457994	1390	1398	diabetic	T038	UMLS:C0011847
28457994	1421	1426	donor	T098	UMLS:C0013018
28457994	1427	1433	tissue	T017	UMLS:C0040300
28457994	1446	1458	CD34(+) CACs	T017	UMLS:C0882849
28457994	1463	1469	plasma	T031	UMLS:C0032105
28457994	1473	1481	diabetic	T038	UMLS:C0011847
28457994	1544	1549	HRECs	T017	UMLS:C0225336
28457994	1555	1563	diabetic	T038	UMLS:C0011847
28457994	1564	1570	donors	T098	UMLS:C0013018
28457994	1593	1598	HRECs	T017	UMLS:C0225336
28457994	1604	1618	tube formation	T038	UMLS:C2752214
28457994	1660	1670	expression	T038	UMLS:C1171362
28457994	1674	1677	ASM	T103	UMLS:C0599122
28457994	1681	1689	diabetic	T038	UMLS:C0011847
28457994	1690	1695	HRECs	T017	UMLS:C0225336
28457994	1707	1715	diabetic	T038	UMLS:C0011847
28457994	1716	1728	CD34(+) CACs	T017	UMLS:C0882849
28457994	1739	1742	ASM	T103	UMLS:C0599122
28457994	1779	1796	endothelial tubes	T017	UMLS:C0014257
28457994	1817	1829	CD34(+) CACs	T017	UMLS:C0882849
28457994	1873	1881	diabetic	T038	UMLS:C0011847
28457994	1934	1942	diabetes	T038	UMLS:C0011847
28457994	1953	1956	ASM	T017	UMLS:C1420259
28457994	1957	1969	upregulation	T038	UMLS:C0041904
28457994	2010	2017	retinal	T017	UMLS:C0035298
28457994	2018	2035	endothelial cells	T017	UMLS:C0225336
28457994	2040	2044	CACs	T017	UMLS:C0882849